Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4999425_CN99425_0